Andrew Cornwell

Dr. Andrew Cornwell is an Adjunct Assistant Professor in the Department of Biomedical Engineering at Case Western Reserve University’s Case School of Engineering. He serves as the Associate Director of the Case-Coulter Translational Research Partnership (CCTRP) and Director of the Case-Cleveland Incubator in the Office of Strategic Partnerships. Additionally, he holds the role of Director for Industrial and Strategic Collaborations at the Cleveland FES Center, bridging academic research with industry and clinical applications across the School of Medicine and School of Engineering.

Dr. Cornwell earned his PhD in Biomedical Engineering from Case Western Reserve University. His early research focused on brain recording and neurotechnology, later transitioning to advancing technology transfer and translational research strategies.

His research interests center on neurotechnology, particularly functional electrical stimulation (FES) systems for rehabilitation and clinical applications. He specializes in accelerating the translation of academic innovations into practical healthcare solutions, focusing on aligning clinical needs, market demands, and research priorities. Key areas include neuroprosthetics, assistive technologies for paralysis, and strategic partnerships to enhance technology commercialization.

Dr. Cornwell’s publications highlight advancements in neurotechnology, including studies on FES systems, brain-computer interfaces, and clinical assessment tools. His work from 2010–2013 emphasizes improving arm mobility for individuals with paralysis, while earlier research (e.g., 2004) explores neural network approaches to predict movements using electrocorticography (ECoG).

While no scientific awards were listed in the provided information, his roles involve managing grants and strategic collaborations through the CCTRP and Cleveland FES Center to fund translational research projects. He is affiliated with the Cleveland FES Center and the Case-Coulter Translational Research Partnership, leading initiatives to commercialize neurotechnology and biomedical innovations.